| Date | Time | Source | Headline | Symbol | Company |
| 07/11/2024 | 12:21PM | iHub Newswire | FeaturedCannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing | | |
| 03/26/2004 | 2:01PM | PR Newswire (US) | SuperGen's New Drug Application for Orathecin(TM) (rubitecan) Capsules Accepted by FDA for Filing | NASDAQ:SUPG | |
| 03/15/2004 | 9:54AM | PR Newswire (US) | MORNING UPDATE: Man Securities Issues Alerts for JNPR, SUPG, VXGN, CECO, and MXT | NASDAQ:SUPG | Supergen, Inc. (MM) |
| 03/10/2004 | 9:00AM | PR Newswire (US) | SuperGen Note Holders Release $10.6 Million in Escrowed Funds | NASDAQ:SUPG | Supergen, Inc. (MM) |
| 03/10/2004 | 7:30AM | PR Newswire (US) | SuperGen Releases Interim Data Clarification From Dacogen(TM) Phase III Clinical Study in Myelodysplastic Syndrome Following Ana | NASDAQ:SUPG | Supergen, Inc. (MM) |
| 03/05/2004 | 12:08PM | PR Newswire (US) | SuperGen Announces Private Placement of $34 Million of Stock and Warrants | NASDAQ:SUPG | |
| 03/02/2004 | 9:00AM | PR Newswire (US) | Published Study Results Show Low-Dose Outpatient Dosing Schedule of Dacogen(TM) Useful in Patients With Hematological Malignanci | NASDAQ:SUPG | |
| 03/01/2004 | 9:32AM | PR Newswire (US) | SuperGen to present at the Wall Street Analyst Forum's 51st New York City Analyst Conference on Tuesday, March 2nd at 10:20 a.m. | NASDAQ:SUPG | |
| 02/26/2004 | 4:00PM | PR Newswire (US) | SuperGen Reports 2003 Fourth Quarter and Year-End Financial Results | NASDAQ:SUPG | |
| 02/25/2004 | 10:25AM | PR Newswire (US) | Webcast Alert: SuperGen Presentation at Informed Investors Biotech/Healthcare Virtual Forum to be Webcast On Thursday, February | NASDAQ:SUPG | Supergen, Inc. (MM) |
| 02/25/2004 | 9:26AM | PR Newswire (US) | SuperGen to Report Fourth-Quarter and Year End Financial Results and Host Conference Call on Thursday, February 26th | NASDAQ:SUPG | Supergen, Inc. (MM) |
| 02/24/2004 | 9:28AM | PR Newswire (US) | SuperGen Acquires European Marketing Authorizations for Nipent(R) from Pfizer | NASDAQ:SUPG | |
| 02/24/2004 | 9:27AM | PR Newswire (US) | SuperGen to present at 6th Annual BIO CEO and Investor Conference on Wednesday, February 25th at 10:30 a.m. (EST) | NASDAQ:SUPG | |
| 02/23/2004 | 7:00AM | PR Newswire (US) | SuperGen Inc. Announces Intent to Withdraw the Registration Statement for Public Offering of Shares of Common Stock | NASDAQ:SUPG | Supergen, Inc. (MM) |
| 02/13/2004 | 8:30AM | PR Newswire (US) | SuperGen Announces Interim Data from Dacogen(TM) Phase III Clinical Study in Myelodysplastic Syndrome | NASDAQ:SUPG | Supergen, Inc. (MM) |
| 01/12/2004 | 9:25AM | PR Newswire (US) | SuperGen Announces the Retirement of Co-Founder and Chief Executive Officer, Joseph Rubinfeld, Ph.D. | NASDAQ:SUPG | Supergen, Inc. (MM) |
| 12/19/2003 | 9:00AM | PR Newswire (US) | SuperGen Provides Update on Nipent(R) and Revises Guidance for 2003 Fourth Quarter and Fiscal Year | NASDAQ:SUPG | Supergen, Inc. (MM) |
| 12/08/2003 | 9:15AM | PR Newswire (US) | Data From Numerous Clinical Studies Cite Activity of Nipent(R) Combination Therapy in Chronic Lymphocytic Leukemia (CLL) | NASDAQ:SUPG | Supergen, Inc. (MM) |
| 12/08/2003 | 9:15AM | PR Newswire (US) | Two Multicenter Clinical Studies Cite Activity of Nipent(R) Combination Therapy in Non-Hodgkin's Lymphoma (NHL) | NASDAQ:SUPG | Supergen, Inc. (MM) |
| 12/05/2003 | 9:15AM | PR Newswire (US) | Dacogen(TM) Data Presented at the 45th Annual Meeting of the American Society of Hematology (ASH) | NASDAQ:SUPG | |
| 12/04/2003 | 9:15AM | PR Newswire (US) | Published Clinical Data Suggests that Dacogen(TM), Administered Subcutaneously, is Active as a Treatment for Sickle Cell Anemia | NASDAQ:SUPG | Supergen, Inc. (MM) |
| 11/17/2003 | 10:32AM | PR Newswire (US) | SuperGen to Present at NYSSA 7th Annual Healthcare Conference | NASDAQ:SUPG | |
| 11/17/2003 | 9:20AM | PR Newswire (US) | Independent Review of Orathecin(TM) Phase III Trial Supports Drug's Activity in Pancreatic Cancer Patients who Failed Prior Trea | NASDAQ:SUPG | |
| 11/17/2003 | 8:30AM | PR Newswire (US) | SuperGen Selected to be Included in NASDAQ Biotechnology Index | NASDAQ:SUPG | |
| 11/14/2003 | 9:30AM | PR Newswire (US) | Preliminary Results of a Study with Nipent(R), Rituxan(TM) and Cyclophosphamide Demonstrate 100 Percent Response Rate in Untreat | NASDAQ:SUPG | Supergen, Inc. (MM) |
| 11/14/2003 | 9:20AM | PR Newswire (US) | Dacogen(TM) Data From Separate Clinical Studies of Imatinib-Refractory and From Untreated Advanced Chronic Myelogenous Leukemia | NASDAQ:SUPG | Supergen, Inc. (MM) |
| 11/04/2003 | 1:05PM | PR Newswire (US) | SuperGen Reports Third-Quarter Financial Results | NASDAQ:SUPG | |
| 11/03/2003 | 4:06PM | PR Newswire (US) | Paulson Investment Presents Annual Smallcap Conference in New York | NASDAQ:SUPG | Supergen, Inc. (MM) |
| 11/03/2003 | 9:15AM | PR Newswire (US) | SuperGen to Report Third-Quarter Financial Results and Host Conference Call on Tuesday, November 4th | NASDAQ:SUPG | |
| 10/30/2003 | 9:34AM | PR Newswire (US) | SuperGen Announces New Executive Promotions And Appointments of Senior Officers | NASDAQ:SUPG | Supergen, Inc. (MM) |